Researchers at the University of Calgary in Canada are conducting further trials after early studies indicated that vitamin B3, or niacin, may help restore immune function in the fight against glioblastoma, an aggressive and difficult-to-treat brain cancer. The findings, while preliminary, suggest that adding niacin to standard radiotherapy and chemotherapy could boost treatment outcomes, though larger clinical studies are needed to confirm these results.
Glioblastoma is known for its rapid growth and resistance to conventional therapies, making it one of the deadliest forms of cancer. The current standard of care includes surgery, radiation, and chemotherapy, but recurrence is common, and the five-year survival rate remains low. The University of Calgary's research offers a potential new avenue by targeting the immune system. Niacin, a common B vitamin, has been shown in early studies to improve the function of immune cells called microglia, which play a role in fighting tumors in the brain.
If confirmed in larger trials, the use of niacin could represent a low-cost, accessible addition to existing treatments. It could also pave the way for combination therapies that include other emerging treatments from companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which is developing therapies for glioblastoma and other central nervous system cancers. CNS Pharmaceuticals is focused on creating novel treatments for brain tumors, and the integration of niacin with such therapies could enhance their efficacy.
The implications of this research extend beyond glioblastoma. If niacin proves effective in restoring immune function in brain cancer, it might be applicable to other cancers where immunosuppression plays a role. However, experts caution that more research is needed before any clinical recommendations can be made. The University of Calgary team is now recruiting patients for larger studies to validate their early findings.
This study highlights the potential of repurposing common vitamins in cancer treatment, a strategy that could offer significant advantages in terms of cost, safety, and availability. Unlike many cancer drugs, niacin is already widely used as a dietary supplement and has a well-established safety profile. This could expedite its integration into treatment protocols if the ongoing trials yield positive results.
For more information on the latest developments in biotechnology and biomedical research, visit BioMedWire.
